The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Open accessAbstract
Management of diabetic kidney disease (DKD) has evolved in parallel with our growing understanding of the multiple interrelated pathophysiological mechanisms that involve hemodynamic, metabolic, and inflammatory pathways. These pathways and others play a vital role in the initiation and progression of DKD. Since its initial discovery, the blockade of the renin-angiotensin system has remained a cornerstone of DKD management, leaving a large component of residual risk to be dealt with. The advent of sodium–glucose cotransporter 2 inhibitors followed by nonsteroidal mineralocorticoid receptor antagonists and, to some extent, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has ushered in a resounding paradigm shift that supports a pillared approach in maximizing treatment to reduce outcomes. This pillared approach is like that derived from the approach to heart failure treatment. The approach mandates that all agents that have been shown in clinical trials to reduce cardiovascular outcomes and/or mortality to a greater extent than a single drug class alone should be used in combination. In this way, each drug class focuses on a specific aspect of the disease's pathophysiology. Thus, in heart failure, β-blockers, sacubitril/valsartan, a mineralocorticoid receptor antagonist, and a diuretic are used together. In this article, we review the evolution of the pillar concept of therapy as it applies to DKD and discuss how it should be used based on the outcome evidence. We also discuss the exciting possibility that GLP-1 RAs may be an additional pillar in the quest to further slow kidney disease progression in diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Zhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., Bixby, H., Cowan, M., Ali, M., Taddei, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00618-8 · Cited by 4,311
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345
Worldwide access to treatment for end-stage kidney disease: a systematic review
Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H. M., Okpechi, I., Zhao, M.-H., Lv, J., Garg, A. X., Knight, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61601-9 · Cited by 2,339
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021) · Circulation · doi:10.1161/circulationaha.120.050686 · Cited by 1,904
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121270 · Cited by 965
de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · Diabetes Care · doi:10.2337/dci22-0027 · Cited by 919
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Self-citationRenal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease
Appel, L. J., Wright, J. T., Greene, T., Agodoa, L. Y., Astor, B. C., Bakris, G. L., Cleveland, W. H., Charleston, J., Contreras, G., Faulkner, M. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0910975 · Cited by 719
Self-citationBakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Self-citationObesity and Risk for Chronic Renal Failure
Ejerblad, E., Fored, C. M., Lindblad, P., Fryzek, J., McLaughlin, J. K., & Nyrén, O. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060638 · Cited by 680
Remodeling of the rat right and left ventricles in experimental hypertension.
Brilla, C. G., Pick, R., Tan, L. B., Janicki, J. S., & Weber, K. T. (1990) · Circulation Research · doi:10.1161/01.res.67.6.1355 · Cited by 674
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Self-citationAldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
Self-citationAngiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
Avosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., & Viberti, G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 492
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
The renin-angiotensin-aldosterone system and its suppression
Ames, M. K., Atkins, C. E., & Pitt, B. (2019) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15454 · Cited by 433
Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function
Carey, R. M., Wang, Z.-Q., & Siragy, H. M. (2000) · Hypertension · doi:10.1161/01.hyp.35.1.155 · Cited by 431
Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., & Schäfer, S. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000091 · Cited by 430
Proinflammatory actions of angiotensins
Ruiz-Ortega, M., Lorenzo, O., Suzuki, Y., Rupérez, M., & Egido, J. (2001) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200105000-00005 · Cited by 412
Usher, M. G., Duan, S. Z., Ivaschenko, C. Y., Frieler, R. A., Berger, S., Schütz, G., Lumeng, C. N., & Mortensen, R. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41080 · Cited by 383
Agarwal, R., Rossignol, P., Romero, A., Garza, D., Mayo, M. R., Warren, S., Ma, J., White, W. B., & Williams, B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32135-x · Cited by 368
Holtkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International · doi:10.1038/ki.2011.79 · Cited by 364
Garg, A. X., Kiberd, B. A., Clark, W. F., Haynes, R. B., & Clase, C. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00356.x · Cited by 355
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 340
Jaisser, F., & Farman, N. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011106 · Cited by 327
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015
Cheng, H.-T., Xu, X., Lim, P. S., & Hung, K.-Y. (2021) · Diabetes Care · doi:10.2337/dc20-1913 · Cited by 315
Astor, B. C., Hallan, S. I., Miller, E. R., Yeung, E., & Coresh, J. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn033 · Cited by 312
Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057983 · Cited by 299
Self-citationLea, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.947 · Cited by 297
Pichler, R., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 295
Grune, J., Beyhoff, N., Smeir, E., Chudek, R., Blumrich, A., Ban, Z., Brix, S., Betz, I. R., Schupp, M., Foryst-Ludwig, A., et al. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10360 · Cited by 292
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
(2015) · PubMed · Cited by 271
Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease
Schmieder, R. E., Mann, J. F. E., Schumacher, H., Gao, P., Mancia, G., Weber, M. A., McQueen, M., Koon, T., & Yusuf, S. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010091001 · Cited by 270
Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial
Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070942 · Cited by 262
Self-citationAngiotensin Receptors and Their Therapeutic Implications
Greindling, K. K., Lassegue, B., & Alexander, R. W. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.001433 · Cited by 262
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.055459 · Cited by 255
Self-citationMechanisms of podocyte injury and implications for diabetic nephropathy
Barutta, F., Bellini, S., & Gruden, G. (2022) · Clinical Science · doi:10.1042/cs20210625 · Cited by 221
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationRossing, P., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Birkenfeld, A. L., McGill, J. B., Rosas, S. E., Joseph, A., Gebel, M., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0294 · Cited by 216
Self-citationMiric, G., Dallemagne, C., Endre, Z., Margolin, S., Taylor, S. M., & Brown, L. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704131 · Cited by 210
Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga
Bakris, G. L., & Molitch, M. (2014) · Diabetes Care · doi:10.2337/dc13-1870 · Cited by 186
Self-citationProvenzano, M., Puchades, M. J., Garofalo, C., Jongs, N., D’Marco, L., Andreucci, M., De Nicola, L., Gorriz, J. L., & Heerspink, H. J. L. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022020207 · Cited by 184
Barrera-Chimal, J., Estrela, G. R., Lechner, S. M., Giraud, S., El Moghrabi, S., Kaaki, S., Kolkhof, P., Hauet, T., & Jaisser, F. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.016 · Cited by 183
Kolkhof, P., Jaisser, F., Kim, S.-Y., Filippatos, G., Nowack, C., & Pitt, B. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_76 · Cited by 180
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Kintscher, U., Bakris, G. L., & Kolkhof, P. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15747 · Cited by 173
Self-citationSulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy
Packham, D. K., Wolfe, R., Reutens, A. T., Berl, T., Heerspink, H. L., Rohde, R., Ivory, S., Lewis, J., Raz, I., Wiegmann, T. B., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040378 · Cited by 171
Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.042 · Cited by 166
Self-citationGreen, J. B., Mottl, A. K., Bakris, G., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rossing, P., Scott, C., Gay, A., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac198 · Cited by 164
Self-citationBello, A. K., Hemmelgarn, B., Lloyd, A., James, M. T., Manns, B. J., Klarenbach, S., & Tonelli, M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09741110 · Cited by 151
Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021) · American Journal of Nephrology · doi:10.1159/000516213 · Cited by 143
Macrophages and Diabetic Nephropathy
Tesch, G. H. (2010) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2010.03.007 · Cited by 137
Katayama, S., Yamada, D., Nakayama, M., Yamada, T., Myoishi, M., Kato, M. C., Nowack, C., Kolkhof, P., & Yamasaki, Y. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.021 · Cited by 137
Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057934 · Cited by 132
Role of Macrophages and Related Cytokines in Kidney Disease
Cantero‐Navarro, E., Rayego‐Mateos, S., Orejudo, M., Tejedor-Santamaria, L., Tejera‐Muñoz, A., Sanz, A. B., Márquez‐Expósito, L., Marchant, V. A., Santos‐Sanchez, L., Egido, J., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.688060 · Cited by 129
Neuen, B. L., Oshima, M., Perkovic, V., Agarwal, R., Arnott, C. G., Bakris, G. L., Cannon, C. P., Charytan, D. M., Edwards, R., Górriz, J. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab497 · Cited by 127
Self-citationHoltkamp, F. A., de Zeeuw, D., de Graeff, P. A., Laverman, G. D., Berl, T., Remuzzi, G., Packham, D., Lewis, J. B., Parving, H. ‐., & Heerspink, H. J. L. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr017 · Cited by 125
Agarwal, R., Pitt, B., Palmer, B. F., Kovesdy, C. P., Burgess, E. D., Filippatos, G. S., Małyszko, J., Ruilope, L. M., Rossignol, P., Rossing, P. R., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac234 · Cited by 124
Self-citationPotential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Mann, J. F. E., Buse, J. B., Idorn, T., Leiter, L. A., Pratley, R. E., Rasmussen, S., Vilsbøll, T., Wolthers, B., & Perkovic, V. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14443 · Cited by 120
Smith, A. C., Toto, R. D., & Bakris, G. L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00055.x · Cited by 117
Self-citationChronic kidney disease in the general population
White, S. L., Cass, A., Atkins, R. C., & Chadban, S. J. (2005) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2004.10.009 · Cited by 115
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
Tesch, G. H., & Young, M. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00313 · Cited by 115
Charytan, D. M., Himmelfarb, J., Ikizler, T. A., Raj, D. S., Hsu, J. Y., Landis, J. R., Anderson, A. H., Hung, A. M., Mehrotra, R., Sharma, S., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.08.034 · Cited by 112
The impact of hyperfiltration on the diabetic kidney
Premaratne, E., Verma, S. K., Ekinci, E. I., Theverkalam, G., Jerums, G., & MacIsaac, R. J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.003 · Cited by 111
Back to the future: glomerular hyperfiltration and the diabetic kidney
Tuttle, K. R. (2017) · Diabetes · doi:10.2337/dbi16-0056 · Cited by 108
Ito, S., Shikata, K., Nangaku, M., Okuda, Y., & Sawanobori, T. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14751218 · Cited by 107
Gaber, L. W., Walton, C., Brown, S. A., & Bakris, G. L. (1994) · Kidney International · doi:10.1038/ki.1994.255 · Cited by 105
Self-citationQuach, K., Lvtvyn, L., Baigent, C., Bueti, J., Garg, A. X., Hawley, C. M., Haynes, R., Manns, B., Perkovic, V., Rabbat, C. G., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.011 · Cited by 105
What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances
Watanabe, K., Sato, E., Mishima, E., Miyazaki, M., & Tanaka, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010570 · Cited by 105
Lawson, C. A., Seidu, S., Zaccardi, F., McCann, G. P., Kadam, U. T., Davies, M. J., Lam, C. S. P., Heerspink, H. J. L., & Khunti, K. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100739 · Cited by 101
Wada, T., Inagaki, M., Yoshinari, T., Terata, R., Totsuka, N., Gotou, M., & Hashimoto, G. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01963-z · Cited by 97
Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells.
Bakris, G., & Ré, R. (1993) · American Journal of Physiology · doi:10.1152/ajprenal.1993.264.6.f937 · Cited by 96
Self-citationKidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease
Tuttle, K. R., McGill, J. B., Haney, D. J., Lin, T. E., & Anderson, P. W. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00840207 · Cited by 94
The physical basis of renal fibrosis: effects of altered hydrodynamic forces on kidney homeostasis
Grabias, B. M., & Κωνσταντόπουλος, Κ. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00503.2013 · Cited by 88
Brilla, C. G., Reams, G. P., Maisch, B., & Weber, K. T. (1993) · PubMed · Cited by 82
The Landscape of Diabetic Kidney Disease in the United States
Duru, O. K., Middleton, T. R., Tewari, M. K., & Norris, K. C. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0980-x · Cited by 81
Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease
Dou, L., & Jourde‐Chiche, N. (2019) · Toxins · doi:10.3390/toxins11100578 · Cited by 79
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A. Z., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14558 · Cited by 73
Self-citationHojs, R., Ekart, R., Bevc, S., & Hojs, N. V. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447434 · Cited by 70
Collard, D., Brouwer, T. F., Engberink, R. O., Zwinderman, A. H., Vogt, L., & van den Born, B. H. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14659 · Cited by 65
Jin, Q., Luk, A. O. Y., Lau, E. S. H., Tam, C. H. T., Ozaki, R., Lim, C. K. P., Wu, H., Jiang, G., Chow, E., Ng, J. K., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.11.011 · Cited by 58
Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease
Nakamura, T., Girerd, S., Jaisser, F., & Barrera‐Chimal, J. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.004 · Cited by 58
Abdominal Obesity, Race and Chronic Kidney Disease in Young Adults: Results from NHANES 1999-2010
Sarathy, H., Henriquez, G., Abramowitz, M. K., Kramer, H., Rosas, S. E., Johns, T. S., Kumar, J., Skversky, A. L., Kaskel, F. J., & Melamed, M. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153588 · Cited by 55
Zareini, B., Blanche, P., D’Souza, M., Malik, M. E., Nørgaard, C. H., Selmer, C., Gislason, G., Kristensen, S. L., Køber, L., Torp-Pedersen, C. T., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.006260 · Cited by 54
on behalf of the ONTARGET/TRANSCEND investigators, Schmieder, R. E., Schutte, R., Schumacher, H., Böhm, M., Mancia, G., Weber, M. A., McQueen, M., Teo, K. K., & Yusuf, S. (2014) · Diabetologia · doi:10.1007/s00125-014-3330-9 · Cited by 45
Ruilope, L. M., Agarwal, R., Chan, J. C. N., Cooper, M. E., Gansevoort, R. T., Haller, H. G., Remuzzi, G., Rossing, P. R., Schmieder, R. E., Nowack, C., et al. (2014) · American Journal of Nephrology · doi:10.1159/000371497 · Cited by 43
Self-citationPatel, R. B., Colangelo, L. A., Reis, J. P., Lima, J. A. C., Shah, S. J., & Lloyd‐Jones, D. M. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4867 · Cited by 40
Major advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
Bakris, G. L. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.009 · Cited by 37
Self-citationKhan, M. S., Bakris, G. L., Shahid, I., Weir, M. R., & Butler, J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.5151 · Cited by 36
Self-citationBlood Pressure Control and Nephroprotection in Diabetes
Abbott, K. C., Basta, E., & Bakris, G. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004263046 · Cited by 30
Self-citationCherney, D. Z. I., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Frederich, R. C., Maldonado, M., Liu, C., Pong, A., Cannon, C. P., et al. (2022) · American Journal of Nephrology · doi:10.1159/000524889 · Cited by 29
Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
Dhaybi, O. A., & Bakris, G. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13983 · Cited by 25
Self-citationPicken, M. M., Long, J., Williamson, G. A., & Polichnowski, A. J. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07749 · Cited by 24
Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System
Poursharif, S., Hamza, S., & Braam, B. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911203 · Cited by 20
Zou, J., Yang, J. W., Zhu, X., Zhong, J., Elshaer, A., Matsusaka, T., Pastan, I. H., Haase, V. H., Yang, H., & Fogo, A. B. (2020) · Kidney International · doi:10.1016/j.kint.2020.09.031 · Cited by 18
Ma, Y., Lin, C., Cai, X., Hu, S., Zhu, X., Lv, F., Yang, W., & Ji, L. (2023) · Acta Diabetologica · doi:10.1007/s00592-022-02022-7 · Cited by 13
Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
Borderie, G., Schnebelen, M., & Baynat, L. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2115776 · Cited by 6
Research works printed but not linked: 4
- Bakris, 1991, Arginine vasopressin stimulates human mesangial cell production of endothelin, J Clin Invest, 87, 1158, 10.1172/JCI115113 · doi:10.1172/jci115113
- Hostetter, 2003, Hyperfiltration and glomerulosclerosis, Semin Nephrol, 23, 194, 10.1053/snep.2003.50017 · doi:10.1053/snep.2003.50017
- Tsimihodimos, 2017, Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition, Curr Vasc Pharmacol, 15, 96, 10.2174/1570161114666161007163426 · doi:10.2174/1570161114666161007163426
- Tostes, 2002, Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension, Clin Sci (Lond), 103, 25S, 10.1042/CS103S025S · doi:10.1042/cs103s025s
Cited by
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Self-citationNeuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358
Self-citationMann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03133-0 · Cited by 200
Self-citationVaduganathan, M., Filippatos, G., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A., Brinker, M., Kolkhof, P., Schloemer, P., Lay-Flurrie, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03264-4 · Cited by 158
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
Metadata
- Authors
- Naaman, S. C., & Bakris, G. L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-08-25
- Volume
- 46
- Issue
- 9
- Pages
- 1574-1586
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4386156942
- Cited by
- 292
- References
- 136
- FWCI
- 47.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.